» Articles » PMID: 35819532

LncRNAs As Epigenetic Regulators of Epithelial to Mesenchymal Transition in Pancreatic Cancer

Overview
Journal Discov Oncol
Publisher Springer
Specialty Oncology
Date 2022 Jul 12
PMID 35819532
Authors
Affiliations
Soon will be listed here.
Abstract

Pancreatic cancer is the leading cause of cancer-related mortality because of tumor metastasis. Activation of the epithelial-to-mesenchymal transition (EMT) pathway has been confirmed to be an important driver of pancreatic cancer progression from initiation to metastasis. Long noncoding RNAs (lncRNAs) have been reported to exert essential physiological functions in pancreatic cancer progression by regulating the EMT program. In this review, we have summarized the role of EMT-related lncRNAs in human pancreatic cancer and the potential molecular mechanisms by which lncRNAs can be vital epigenetic regulators of epithelial to mesenchymal transition. Specifically, EMT-activating transcription factors (EMT-TFs) regulate EMT via TGF-β/Smad, Wnt/β-catenin, and JAK/STAT pathways. In addition, the interaction between lncRNAs and HIF-1α and m6A RNA methylation also have an impact on tumor metastasis and EMT in pancreatic cancer. This review will provide insights into lncRNAs as promising biomarkers for tumor metastasis and potential therapeutic strategies for pancreatic cancer.

Citing Articles

N-Methylandenosine-related lncRNAs as potential biomarkers for predicting prognosis and the immunotherapy response in pancreatic cancer.

Bai Z, Xia Q, Xu W, Wu Z, He X, Zhang X Cell Mol Life Sci. 2025; 82(1):48.

PMID: 39833465 PMC: 11753445. DOI: 10.1007/s00018-024-05573-w.


Plasma-derived exosomal long noncoding RNAs of pancreatic cancer patients as novel blood-based biomarkers of disease.

He X, Chen L, Di Y, Li W, Zhang X, Bai Z BMC Cancer. 2024; 24(1):961.

PMID: 39107726 PMC: 11301836. DOI: 10.1186/s12885-024-12755-z.


Molecular Mechanisms and Clinical Implications of Noncoding RNAs in Cancer.

Wang J, He X, Corpe C Noncoding RNA. 2024; 10(4).

PMID: 39051371 PMC: 11270368. DOI: 10.3390/ncrna10040037.


Melatonin and Its Role in the Epithelial-to-Mesenchymal Transition (EMT) in Cancer.

Martinez-Campa C, Alvarez-Garcia V, Alonso-Gonzalez C, Gonzalez A, Cos S Cancers (Basel). 2024; 16(5).

PMID: 38473317 PMC: 10931174. DOI: 10.3390/cancers16050956.


Epigenetic priming of an epithelial enhancer by p63 and CTCF controls expression of a skin-restricted gene XP33.

Smirnov A, Lena A, Tosetti G, Yang X, Cappello A, Helmer Citterich M Cell Death Discov. 2023; 9(1):446.

PMID: 38065940 PMC: 10709559. DOI: 10.1038/s41420-023-01716-3.


References
1.
Lin Y, Jian Z, Jin H, Wei X, Zou X, Guan R . Long non-coding RNA DLGAP1-AS1 facilitates tumorigenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via the feedback loop of miR-26a/b-5p/IL-6/JAK2/STAT3 and Wnt/β-catenin pathway. Cell Death Dis. 2020; 11(1):34. PMC: 6965175. DOI: 10.1038/s41419-019-2188-7. View

2.
Li H, Wang X, Wen C, Huo Z, Wang W, Zhan Q . Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic cancer. Mol Cancer. 2017; 16(1):169. PMC: 5679488. DOI: 10.1186/s12943-017-0738-0. View

3.
Schizas D, Charalampakis N, Kole C, Economopoulou P, Koustas E, Gkotsis E . Immunotherapy for pancreatic cancer: A 2020 update. Cancer Treat Rev. 2020; 86:102016. DOI: 10.1016/j.ctrv.2020.102016. View

4.
Dorn A, Glass M, Neu C, Heydel B, Huttelmaier S, Gutschner T . LINC00261 Is Differentially Expressed in Pancreatic Cancer Subtypes and Regulates a Pro-Epithelial Cell Identity. Cancers (Basel). 2020; 12(5). PMC: 7281485. DOI: 10.3390/cancers12051227. View

5.
Wu L, Liu Y, Guo C, Shao Y . LncRNA OIP5-AS1 promotes the malignancy of pancreatic ductal adenocarcinoma via regulating miR-429/FOXD1/ERK pathway. Cancer Cell Int. 2020; 20:296. PMC: 7346488. DOI: 10.1186/s12935-020-01366-w. View